Skip to main content
Stuart Schnitt, MD, Pathology, Boston, MA

StuartJSchnittMD

Pathology Boston, MA

Anatomic Pathology, Clinical Pathology

Professor of Pathology, Harvard Medical School; Chief of Breast Oncologic Pathology, Dana-Farber/Brigham and Women's Cancer Center

Dr. Schnitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schnitt's full profile

Already have an account?

  • Office

    75 Francis St
    Boston, MA 02115
    Phone+1 617-732-7510
    Fax+1 617-264-5118

Summary

  • Stuart J. Schnitt, M.D. is the Chief of Breast Oncologic Pathology for the Dana-Farber/Brigham and Women’s Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital Breast Oncology Program, co-leader of the Dana Farber Harvard Cancer Center Breast Program, Senior Pathologist at Brigham and Women’s Hospital, a Professor of Pathology at Harvard Medical School and an internationally recognized expert in breast pathology.

    Dr. Schnitt did his internship and residency in Anatomic and Clinical Pathology at Beth Israel Hospital in Boston followed by a fellowship in surgical pathology, also at Beth Israel Hospital. He was a faculty member in the Beth Israel Hospital/Beth Israel Deaconess Medical Center Department of Pathology from 1984-2017, including 11 years as Director of Anatomic Pathology and subsequently Vice Chair for Anatomic Pathology. He has published over 340 original articles, review articles, editorials, commentaries, and book chapters, primarily in the area of breast diseases. He has authored a popular breast pathology textbook entitled “Biopsy Interpretation of the Breast”, now its third edition. The first two editions of this book were also published in Chinese. In addition, he is one of the editors of the 4th Edition of the “World Health Organization Classification of Tumours of the Breast”, published in 2012.

    Dr. Schnitt is a Past President of the United States and Canadian Academy of Pathology (2010-2011). Other notable honors include the Arthur Purdy Stout Society of Surgical Pathologists Annual Prize (1999), the Albany Medical College Distinguished Alumnus award (2014), the Lynn Sage Distinguished Lecturer (2014) and the Maude Abbot Lecture at the United States and Canadian Academy of Pathology Annual Meeting (2016).

Education & Training

  • Beth Israel Deaconess Medical Center/Harvard Medical School GI Pathology
    Beth Israel Deaconess Medical Center/Harvard Medical School GI PathologyFellowship, Selective Pathology, 1983 - 1984
  • Beth Israel Deaconess Medical Center/Harvard Medical School
    Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Pathology-Anatomic and Clinical, 1979 - 1983
  • Albany Medical College
    Albany Medical CollegeClass of 1979

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1983 - 2025
  • American Board of Pathology Anatomic Pathology & Clinical Pathology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • Boston Magazine Castle Connolly, 2008-2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Histopathologic Findings in Breast Surgical Specimens from Patients Undergoing Female-to-Male Gender Reassignment Surgery  
    Stuart Schnitt, MD, Nature

Press Mentions

  • International Multi-Site Study of Ibex Medical Analytics’ AI-Powered Solution Demonstrates Improved HER2 Biomarker Scoring in Breast Cancer
    International Multi-Site Study of Ibex Medical Analytics’ AI-Powered Solution Demonstrates Improved HER2 Biomarker Scoring in Breast CancerOctober 15th, 2024
  • Institut Curie Study Published in a Nature Journal Reporting Excellent Outcomes of Ibex's AI Solution for Breast Cancer Detection
    Institut Curie Study Published in a Nature Journal Reporting Excellent Outcomes of Ibex's AI Solution for Breast Cancer DetectionDecember 21st, 2022
  • Ibex Reports Positive Outcomes for AI-Supported Diagnosis of Breast Cancer
    Ibex Reports Positive Outcomes for AI-Supported Diagnosis of Breast CancerSeptember 2nd, 2022
  • Join now to see all

Grant Support

  • C-1: Tissue And PathologyNational Cancer Institute2005–2007
  • Core--Human Breast Cancer PathologyNational Cancer Institute2000